ICUI

+ Watchlist + Portfolio

ICU Medical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $187.26
52-Week Range: $112.50 – $192.85
Market Cap: $4.56B
P/E (TTM): 152.11
EPS (TTM): 1.20
Dividend Yield: —

Advanced Metrics

Price/Book: 2.12
PEG Ratio: 0.10
Return on Equity: 1.41%
Return on Assets: 2.22%
Gross Margin: 39.13%
Operating Margin: 10.95%
Profit Margin: 1.39%
Current Ratio: 2.43
Debt/Equity: 0.60
Total Debt: $1.29B
Free Cash Flow: $175.37M
Revenue Growth: 0.50%
Earnings Growth: -46.90%
Enterprise Value: $5.67B

ICUI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.28B	$2.26B	$2.38B	$2.23B
Cost of Revenue	$1.58B	$1.52B	$1.56B	$1.41B
Gross Profit	$697.76M	$739.87M	$824.78M	$822.04M
Research & Development	$92.98M	$85.34M	$88.61M	$87.50M
Selling, General & Admin	$608.35M	$606.69M	$638.76M	$625.21M
Operating Expenses	$701.33M	$692.04M	$727.38M	$712.71M
Operating Income	-$3.57M	$47.84M	$97.41M	$109.33M
EBITDA	$191.55M	$253.20M	$260.04M	$298.44M
Pretax Income	-$114.41M	-$78.30M	-$66.01M	$4.36M
Income Tax	-$40.12M	-$48.64M	$51.68M	$2.44M
Net Income	-$74.29M	-$29.66M	-$117.69M	$732.00K
Diluted EPS	-3.11	-1.23	-4.83	0.03
Diluted Shares	23.87M	24.09M	24.39M	24.90M

ICUI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$208.78M	$254.22M	$308.57M	$307.96M
Receivables	$246.90M	$182.15M	$200.14M	$203.91M
Inventory	$696.01M	$709.36M	$584.68M	$615.86M
Current Assets	$1.24B	$1.22B	$1.44B	$1.19B
Total Assets	$4.52B	$4.38B	$4.20B	$4.05B
Current Liabilities	$494.56M	$481.84M	$556.18M	$498.86M
Long-Term Debt	$1.62B	$1.58B	$1.53B	$1.27B
Total Debt	$1.73B	$1.70B	$1.63B	$1.33B
Total Liabilities	$2.43B	$2.26B	$2.24B	$1.93B
Retained Earnings	$837.50M	$807.85M	$690.16M	$690.89M
Shareholders' Equity	$2.09B	$2.12B	$1.97B	$2.12B
Working Capital	$740.64M	$739.43M	$885.80M	$691.69M
Net Debt	$1.44B	$1.37B	$1.27B	$976.70M

ICUI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$62.13M	$166.20M	$204.03M	$179.85M
Capital Expenditure	-$99.33M	-$93.67M	-$90.21M	-$97.02M
Free Cash Flow	-$161.46M	$72.53M	$113.83M	$82.83M
Depreciation & Amortisation	$235.15M	$228.77M	$219.51M	$200.74M
Stock-Based Compensation	$36.02M	$40.56M	$46.88M	$55.76M
Investing Cash Flow	-$1.91B	-$87.95M	-$88.96M	$122.23M
Financing Cash Flow	$1.64B	-$35.98M	-$55.80M	-$311.52M
Net Change in Cash	-$334.56M	$42.27M	$59.27M	-$9.45M

ICUI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$604.70M	$548.87M	$536.99M	$540.70M	$530.23M
Cost of Revenue	$394.59M	$340.80M	$336.11M	$337.72M	$324.00M
Gross Profit	$210.11M	$208.06M	$200.88M	$202.99M	$206.23M
Research & Development	$23.29M	$21.87M	$21.25M	$21.09M	$21.28M
Selling, General & Admin	$157.23M	$159.39M	$152.77M	$155.81M	$154.57M
Operating Expenses	$180.52M	$181.26M	$174.02M	$176.90M	$175.85M
Operating Income	$29.59M	$26.80M	$26.86M	$26.09M	$30.38M
EBITDA	$63.80M	$106.41M	$70.52M	$57.71M	$64.56M
Pretax Income	-$10.91M	$33.68M	-$2.51M	-$15.90M	-$3.98M
Income Tax	$4.57M	$1.18M	-$658.00K	-$2.65M	-$34.71M
Net Income	-$15.48M	$35.34M	-$3.40M	-$15.73M	$30.13M
Diluted EPS	-0.63	1.43	-0.14	-0.64	1.20
Diluted Shares	24.54M	24.71M	24.69M	24.69M	25.18M

ICUI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$289.70M	$300.02M	$299.73M	$307.96M	$288.33M
Receivables	$204.68M	$219.17M	$217.23M	$203.91M	$226.82M
Inventory	$590.33M	$616.47M	$622.44M	$615.86M	$605.59M
Current Assets	$1.42B	$1.18B	$1.21B	$1.19B	$1.21B
Total Assets	$4.18B	$4.11B	$4.10B	$4.05B	$4.01B
Current Liabilities	$549.02M	$482.78M	$492.90M	$498.86M	$517.90M
Long-Term Debt	$1.49B	$1.34B	$1.31B	$1.27B	$1.26B
Total Debt	$1.60B	$1.39B	$1.36B	$1.33B	$1.33B
Total Liabilities	$2.20B	$1.99B	$1.98B	$1.93B	$1.90B
Retained Earnings	$674.68M	$710.02M	$706.62M	$690.89M	$721.02M
Shareholders' Equity	$1.99B	$2.12B	$2.13B	$2.12B	$2.11B
Working Capital	$874.89M	$697.34M	$714.39M	$691.69M	$695.34M
Net Debt	$1.25B	$1.04B	$1.01B	$976.70M	$992.25M

ICUI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$51.33M	$11.21M	$56.71M	$60.60M	$38.91M
Capital Expenditure	-$16.85M	-$22.00M	-$31.75M	-$26.41M	-$13.21M
Free Cash Flow	$34.47M	-$10.79M	$24.96M	$34.19M	$25.70M
Depreciation & Amortisation	$49.45M	$49.66M	$50.80M	$50.83M	$50.00M
Stock-Based Compensation	$12.18M	$14.46M	$15.24M	$13.88M	$14.01M
Investing Cash Flow	-$16.81M	$187.46M	-$30.03M	-$18.39M	-$11.21M
Financing Cash Flow	-$56.34M	-$195.01M	-$25.69M	-$34.48M	-$44.12M
Net Change in Cash	-$21.82M	$3.65M	$993.00K	$7.72M	-$16.42M

Market Snapshot

About

ICU Medical is a medical device company developing, manufacturing, and selling innovative medical products used in infusion therapy, oncology, and critical care applications. The company's product portfolio includes IV therapy systems, infusion pumps, dedicated and non-dedicated IV sets, needleless connector products, and closed system transfer devices for hazardous drug handling. ICU Medical serves hospitals, clinics, ambulatory care centers, and other healthcare facilities worldwide. The company has grown through internal innovation and strategic acquisitions, including the acquisition of Smiths Medical's infusion systems and vascular access product lines, making it a comprehensive provider of infusion therapy solutions.